ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2026

MicroRNA-27a Can Contribute to Interferon Signatures in Systemic Lupus Erythematosus via the Suppression of Tripartite Motif-containing Protein 27

Daiga Kishimoto1, Ryusuke Yoshimi 1, Yosuke Kunishita 1, Yumiko Sugiyama 2, Takaaki Komiya 1, Natsuki Sakurai 3, Reikou Kamiyama 1, Yohei Kirino 4 and Hideaki Nakajima 4, 1Department of Stem Cell and Immune Regulation / Yokohama City University Graduate School of Medicine, Yokohama, Japan, 2Department of Rheumatic Diseases / Yokohama City University Medical Center, Yokohama, Japan, 3Department of Stem Cell and Immune Regulation / Yokohama City University Graduate School of Medicine, Yokohama City, Japan, 4Department of Stem Cell and Immune Regulation, Yokohama City University Graduate School of Medicine, Yokohama, Japan

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: interferons, MicroRNA and innate immunity, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 12, 2019

Title: SLE – Etiology & Pathogenesis Poster II

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Type Ⅰ interferons (IFN) contribute to antiviral innate immune responses. Upon viral infection, pattern recognition receptors trigger TANK-binding kinase 1 (TBK1) activation and lead to activation of the transcription factor IFN regulatory factor (IRF) 3 to induce type Ⅰ IFN production. Because high expression of typeⅠ IFN inducible genes, called IFN signature, is observed in systemic lupus erythematosus (SLE), the excessive IFN production has been thought to have the important role in SLE pathogenesis.

Recently, it has been reported that silica acid-binding immunoglobulin-like lectin (Siglec) 1 suppresses antiviral innate immune response by inducing TBK1 degradation by the E3 ubiquitin ligase, tripartite motif-containing protein (TRIM) 27. It has also been reported that type Ⅰ IFN-induced downregulation of microRNA (miR)-27a can increase TRIM27 expression, and then inhibit the type Ⅰ IFN production in antiviral innate response.

Here, we report that downregulation of TRIM27 by miR-27a can contribute to IFN signature in SLE.

Methods: Human peripheral blood mononuclear cells (PBMC) and sera were obtained from SLE patients and healthy controls (HC). All of the patients fulfilled the revised 1997 ACR Criteria for Classification of SLE. The quantitative real-time PCR (qPCR) and western blotting were performed to assess the mRNA and protein expression levels of TRIM27 and TBK1, respectively. Serum miR-27a levels were investigated by qPCR. Statistical analysis was performed by using the GraphPad Prism. Data are presented as mean ± SEM. We used a Student’s t-test or the two-tailed Mann-Whitney U test. The p-values < 0.05 were considered statistically significant.

Results: The expression level of miR-27a in sera of SLE patients was higher than that of HC (p=0.0043; Figure 1A). The expression levels of mRNA and protein of TRIM27 in PBMC of SLE patients were lower than those of HC (p=0.020, p=0.038, respectively; Figure 1B, C). On the contrary, TBK1 protein level was higher in SLE patients as compared to HC (p=0.0079; Figure 2A, B).

Conclusion: In SLE patients, increased miR-27a expression may induce downregulation of TRIM27, which leads to reduction of the TBK1 ubiquitination and degradation. The results suggest that miR-27a can contribute to interferon signatures in SLE via the suppression of TRIM27.


ACR2019_figure1 for abstract_Kishimoto_final

Figure 1. Increased miRNA-27a expression may induce downregulation of TRIM27 in SLE patients
-A-The expression level of miR-27a in sera of SLE patients was higher than that of HC -p=0.0043-. The expression levels of mRNA -B- and protein -C- of TRIM27 in PBMC of SLE patients were lower than those of HC -p=0.020, p=0.038, respectively-. Data are presented as mean ± SEM. Statistically significant data -*, p< 0.05 and **, p < 0.01- by Student’s t-test or two-tailed Mann-Whitney U test.


ACR2019_figure2 for abstract_Kishimoto_final

Figure 2. TBK1 protein level is higher in SLE patients.
-A- Western blot analysis was performed with extracts from PBMC of SLE patients and HC using anti-TBK1 Ab. β-actin was used as a loading control. -B- TBK1 protein level was higher in SLE patients as compared to HC -n=5 in each groups-. Data are presented as mean ± SEM. Statistically significant data -**, p < 0.01- by Student’s t-test.


Disclosure: D. Kishimoto, None; R. Yoshimi, None; Y. Kunishita, None; Y. Sugiyama, None; T. Komiya, None; N. Sakurai, None; R. Kamiyama, None; Y. Kirino, None; H. Nakajima, None.

To cite this abstract in AMA style:

Kishimoto D, Yoshimi R, Kunishita Y, Sugiyama Y, Komiya T, Sakurai N, Kamiyama R, Kirino Y, Nakajima H. MicroRNA-27a Can Contribute to Interferon Signatures in Systemic Lupus Erythematosus via the Suppression of Tripartite Motif-containing Protein 27 [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/microrna-27a-can-contribute-to-interferon-signatures-in-systemic-lupus-erythematosus-via-the-suppression-of-tripartite-motif-containing-protein-27/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/microrna-27a-can-contribute-to-interferon-signatures-in-systemic-lupus-erythematosus-via-the-suppression-of-tripartite-motif-containing-protein-27/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology